COMPOUNDS AND METHODS

This invention relates to 3,4-dinitrobenzamide compounds which are ligands, in particular, antagonists, of the Calcitonin Gene-Related Peptide ("CGRP") receptor. In addition, this invention relates to the treatment and prevention of disease states mediated by CGRP, including, but not limit...

Full description

Saved in:
Bibliographic Details
Main Author DAINES, ROBERT, A
Format Patent
LanguageEnglish
French
Published 12.03.1998
Edition6
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This invention relates to 3,4-dinitrobenzamide compounds which are ligands, in particular, antagonists, of the Calcitonin Gene-Related Peptide ("CGRP") receptor. In addition, this invention relates to the treatment and prevention of disease states mediated by CGRP, including, but not limited to, headaches, especially migraines; non-insulin dependent diabetes mellitus; neurogenic inflammation; cardiovascular disorders; chronic inflammation; pain; endotoxic shock; arthritis; allergic rhinitis; allergic contact dermatitis; inflammatory skin conditions; and asthma, all in mammals, by the use of 3,4-dinitrobenzamide CGRP receptor antagonists. Cette invention concerne des composés 3,4-dinitrobenzamide, lesquels sont des ligands, notamment des antagonistes, du récepteur du peptide lié au gène de la Calcitonine ("CGRP"). De plus, cette invention concerne le traitement et la prévention d'états pathologiques induits par CGRP, y compris, de façon non limitative les maux de tête, notamment les migraines; le diabète sucré non insulino-dépendant, l'inflammation neurogène, les troubles cardio-vasculaires, l'inflammation chronique, la douleur, le choc endotoxique, l'arthrite, les rhinites allergiques, l'eczéma de contact allergique, les états cutanés inflammatoires ainsi que l'asthme, tous chez des mammifères, par l'utilisation d'antagonistes 3,4-dinitrobenzamide du récepteur du CGRP.
Bibliography:Application Number: WO1997US15931